Phase I/II Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT

Researchers conducted a Phase I/II trial evaluating high-dose palifermin for preventing severe chronic GVHD in matched unrelated donor T cell replete peripheral-blood HCT following reduced-intensity conditioning.